

Title (en)
IL-8 RECEPTOR ANTAGONISTS

Title (de)
IL-8-REZEPTORANTAGONISTEN

Title (fr)
ANTAGONISTES DU RECEPTEUR IL-8

Publication
EP 0920253 A4 20011017 (EN)

Application
EP 97939515 A 19970815

Priority
• US 9714825 W 19970815
• US 2399196 P 19960815

Abstract (en)
[origin: WO9806262A1] This invention relates to the use of compounds of formula (I) in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). The variables of (I) are defined herein.

IPC 1-7
C07C 279/18; **C07C 279/28**; **C07C 335/16**; **A61K 31/355**

IPC 8 full level
A61P 1/04 (2006.01); **A61K 31/155** (2006.01); **A61P 7/02** (2006.01); **A61P 9/02** (2006.01); **A61P 9/10** (2006.01); **A61P 11/00** (2006.01); **A61P 11/06** (2006.01); **A61P 13/12** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 25/28** (2006.01); **A61P 37/06** (2006.01); **C07C 279/18** (2006.01); **C07C 279/22** (2006.01); **C07C 279/24** (2006.01); **C07C 279/28** (2006.01); **C07C 335/16** (2006.01)

CPC (source: EP)
A61P 1/04 (2017.12); **A61P 7/02** (2017.12); **A61P 9/02** (2017.12); **A61P 9/10** (2017.12); **A61P 11/00** (2017.12); **A61P 11/06** (2017.12); **A61P 13/12** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 25/28** (2017.12); **A61P 37/06** (2017.12); **C07C 279/18** (2013.01); **C07C 279/28** (2013.01); **C07C 335/16** (2013.01)

Citation (search report)
• [E] EP 0790240 A1 19970820 - TANABE SEIYAKU CO [JP]
• See references of WO 9806262A1

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9806262 A1 19980219; EP 0920253 A1 19990609; EP 0920253 A4 20011017; JP 2001527519 A 20011225

DOCDB simple family (application)
US 9714825 W 19970815; EP 97939515 A 19970815; JP 51011798 A 19970815